纤维化
心脏纤维化
肌成纤维细胞
医学
心力衰竭
细胞外基质
心肌纤维化
心肌梗塞
成纤维细胞
体内
癌症研究
发病机制
心功能曲线
药理学
病理
内科学
生物
细胞生物学
体外
生物技术
生物化学
作者
Paolo Morfino,Alberto Aimo,Vincenzo Castiglione,M. Emdin
出处
期刊:PubMed
日期:2023-07-01
卷期号:24 (7): 508-520
摘要
Cardiac fibrosis is characterized by the deposition of extracellular matrix proteins in the spaces between cardiomyocytes following both acute and chronic tissue damage events, resulting in the remodeling and stiffening of heart tissue. Fibrosis plays an important role in the pathogenesis of many cardiovascular disorders, including heart failure and myocardial infarction. Several studies have identified fibroblasts, which are induced to differentiate into myofibroblasts in response to various types of damage, as one of the most important cell types involved in the fibrotic process. There are currently no drugs with primarily antifibrotic action approved for clinical use, as the evidence of a clinical efficacy of these drugs is extremely limited, despite the numerous encouraging results from experimental studies. A new approach is represented by the use of chimeric antigen receptor T cells engineered in vivo using lipid nanoparticles containing mRNA encoding a receptor directed against the fibroblast activation protein, expressed by activated cardiac fibroblasts. This strategy has proved to be safe and effective in reducing myocardial fibrosis and improving cardiac function in mouse models of cardiac fibrosis. Clinical studies are required to test this novel approach in humans.
科研通智能强力驱动
Strongly Powered by AbleSci AI